- Home
- GCMG vs EYPT Comparison
GCMG vs EYPT Comparison
Compare GCMG & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- EYPT
- Stock Information
- Founded
- GCMG 1971
- EYPT 1987
- Country
- GCMG United States
- EYPT United States
- Employees
- GCMG N/A
- EYPT N/A
- Industry
- GCMG Finance/Investors Services
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- GCMG Finance
- EYPT Industrials
- Exchange
- GCMG Nasdaq
- EYPT Nasdaq
- Market Cap
- GCMG 631.4M
- EYPT 741.0M
- IPO Year
- GCMG N/A
- EYPT 2005
- Fundamental
- Price
- GCMG $13.05
- EYPT $11.83
- Analyst Decision
- GCMG Buy
- EYPT Strong Buy
- Analyst Count
- GCMG 4
- EYPT 7
- Target Price
- GCMG $15.13
- EYPT $24.29
- AVG Volume (30 Days)
- GCMG 590.1K
- EYPT 657.3K
- Earning Date
- GCMG 08-07-2025
- EYPT 08-06-2025
- Dividend Yield
- GCMG 3.37%
- EYPT N/A
- EPS Growth
- GCMG N/A
- EYPT N/A
- EPS
- GCMG 0.19
- EYPT N/A
- Revenue
- GCMG $533,097,999.00
- EYPT $51,898,000.00
- Revenue This Year
- GCMG $2.72
- EYPT N/A
- Revenue Next Year
- GCMG $12.99
- EYPT N/A
- P/E Ratio
- GCMG $70.21
- EYPT N/A
- Revenue Growth
- GCMG 15.56
- EYPT 2.99
- 52 Week Low
- GCMG $10.04
- EYPT $3.91
- 52 Week High
- GCMG $14.48
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- GCMG 69.54
- EYPT 67.14
- Support Level
- GCMG $12.69
- EYPT $10.84
- Resistance Level
- GCMG $13.04
- EYPT $11.50
- Average True Range (ATR)
- GCMG 0.32
- EYPT 0.76
- MACD
- GCMG 0.04
- EYPT 0.10
- Stochastic Oscillator
- GCMG 91.18
- EYPT 88.61
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.